Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$3.59 - $5.0 $17 - $25
-5 Closed
0 $0
Q2 2021

Aug 17, 2021

BUY
$4.63 - $8.0 $23 - $40
5 New
5 $0

Others Institutions Holding GLTO

About Galecto, Inc.


  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $186M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track This Portfolio

Track Salem Investment Counselors Inc Portfolio

Follow Salem Investment Counselors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Salem Investment Counselors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Salem Investment Counselors Inc with notifications on news.